Preparation of nasal temperature-sensitive in situ gel of Radix Bupleuri and evaluation of the febrile response mechanism

Drug Development and Industrial Pharmacy

Volumn 36, Issue 4, 2010, Pages 490-496

  Chen, En ^a   Chen, Jun ^a   Cao, Shi Lei ^a   Zhang, Qi Zhi ^a   Jiang, Xin Guo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CAMP; Fever cooling; In situ gel; Nasal delivery system; Pharmacodynamics; Poloxamer; Radix Bupleuri

Indexed keywords

BUPLEURUM ROOT EXTRACT; CYCLIC AMP; MACROGOL 4000; NOSE SPRAY; POLOXAMER; ANALGESIC AGENT; BACTERIAL POLYSACCHARIDE; EXCIPIENT; GEL; GELLAN; HERBACEOUS AGENT; PLANT EXTRACT; VEGETABLE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPYRETIC ACTIVITY; ARTICLE; BODY TEMPERATURE; BUPLEURUM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULARY; DRUG FORMULATION; DRUG RELEASE; DRUG RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; FEVER; GEL; GELATION; IN VITRO STUDY; MALE; NONHUMAN; NOSE CAVITY; NOSE TEMPERATURE; PHASE TRANSITION; RABBIT; TEMPERATURE; TEMPERATURE SENSITIVITY; ANIMAL; CHEMISTRY; DRUG STABILITY; INTRANASAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; METABOLISM; PHYTOTHERAPY; VISCOSITY;

ADMINISTRATION, INTRANASAL; ANALGESICS, NON-NARCOTIC; ANIMALS; BODY TEMPERATURE; BUPLEURUM; CYCLIC AMP; DRUG STABILITY; DRUGS, CHINESE HERBAL; EXCIPIENTS; FEVER; GELS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT OILS; POLYSACCHARIDES, BACTERIAL; RABBITS; VISCOSITY;

EID: 77749268062     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903264371     Document Type: Article

References (29)

1. Chang HM, But PHH. (1987). Pharmacology and application of Chinese materia medica. Singapore: World Scientific Publishing.
2. Xie YL, Lu W, Cao SL, Jiang XG, Yin M, Tang WL. (2006). Preparation of Bupleurum nasal spray and evaluation on its safety and efficacy. Chem Pharm Bull, 54:48-53.
3. Cao AX. (1999). Cases of antipyretic effect by Radix Bupleuri nasal solutions. J Pract Tradit Chin Med, 15:15-6.
4. Gizurason S. (1993). The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev, 11:329-47.
5. Illum L, Jorgensen H, Bisgaard H, Krogsgaard O, Rossing N. (1987). Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm, 39:189-99.
6. Wei G, Liu WY, Zheng JM. (2004). Diffusion behaviors of drugs in thermosensitive in situ gels. Acta Pharm Sin, 9:232-5.
7. Desai SD, Blanchard J. (1998). Evaluation of Pluronic F127 sustained-release ocular delivery systems for Pilocarpine using the albino rabbit eye model. Pharm Sci, 87:1190-5.
8. Cohen S, Lobel E, Trevgoda A. (1997). A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release, 44:201-08.
9. Srividya B, Cardoza RM, Amin PD. (2001). Sustained ophthalmic delivery of Ofloxacin from a pH triggered in situ gelling system. J Control Release, 73:205-11.
10. Hatefi A, Amsden B. (2002). Biodegradable injectable in situ forming drug delivery systems. J Control Release, 80:9-28.
11. Hubbell JA, Pathak CP, Sawhney AS, et al. (1995). Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled release carriers. US patent no. 5410016.
12. Okuzaki H, Osada Y. (1994). Electro-driven chemomechanical polymer gel as an intelligent soft material. J Biomater Sci Polym Ed, 5:485-96.
13. Philipp DWK. (1976). Evidence for the involvement of adenosine 3′,5′-cyclic monophosphate in fever genesis. Pfügers Arch, 362:223-7.
14. Willies GH, Wolf CJ, Rosendorff C. (1976). The effect of an inhibitor of adenylate cyclase on the development of pyrogen, prostaglandin and cyclic AMP fevers in the rabbit. Pfügers Arch, 367:177-81.
15. Schmolka IR, Biomed J. (1972). Fever and anapyrexia in systemic inflammation: Intracellular signaling by cyclic nucleotides. Mater Res, 6:571.
16. Lorin MI, Gaerlan PF, Mandel ID. (1972). Quantitative composition of nasal secretions in normal subjects. J Lab Clin Med, 80:275-81.
17. Mai M, Samar M, Nahed DM, Seham SAE. (2008). Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm, 34:744-52.
18. Jiang XG, Cui JB, Fang XL, Wei Y, Xi NZ. (1995). Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharm Sin, 30:848-53.
19. Cao SL, Chen E, Zhang QZ, Jiang XG. (2007). A novel nasal delivery system of a Chinese traditional medicine, Radix Bupleuri, based on the concept of ion-activated in situ gel. Arch Pharm Res, 30:1014-9.
20. Du Y, Huang QQ, He ZM, Li GM. (2003). Studies on rabbit's tolerance to bacterioendotoxin's pyrogen in pyrogen test. Lab Anim Sci Manage, 20:13-5.
21. Goudah A, Mouneir SM, Shim JH, Abd EAA. (2006). Influence of endotoxin induced fever on the pharmacokinetics of intramuscularly administered cefepime in rabbits. J Vet Sci, 7:151-5.
22. Van DBM, Romeijn SG, Verhoef JC, Merkus FW. (2002). Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods, 116:99-107.
23. Shi ZQ, Zhang QZ, Jiang XG. (2005). Enhancement of systemic and CNS delivery of meptazinol hydrochloride by intranasal administration to rats. Acta Pharm Sin, 40:754-7.
24. Amal EK, Mona EK. (2006). Thermally reversible in situ gelling carbamazepine liquid suppository. Drug Deliv, 13:143-8.
25. Katarina E, Johan C, Roger P. (1998). Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci, 6:105-12.
26. Wei G, Zheng JM, Li SM. (2002). Studies on Thermosensitive in Situ Gels for Ophthalmic Use. China: Shenyang Pharmaceutical University.
27. Zhang QZ, Zha LS, Zhang Y, Jiang WM, Lu W, Shi ZQ, et al. (2006). The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J Drug Target, 14:281-90.
28. Chen J, Jiang XG, Jiang WM, Gao XL, Mei N. (2005). Intranasal absorption of rizatriptan - in vivo pharmacokinetics and bioavailability study in humans. Pharmazie, 60:39-41.
29. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. (2005). Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release, 107:428-48.